GC027 Shows Promise as Therapy for Adult Relapsed, Refractory T-Cell ALL
All 5 patients had a complete response or complete response with incomplete hematologic recovery, and 4 of the 5 patients were minimal residual disease–negative.
Hematologic Cancers
Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
Deep and Durable Responses to Double Anti-BCMA, Single-Domain Antibody CAR-T Therapies Seen in RRMM
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Dual-Targeting CAR-T Appears Active in R/R DLBCL
The Alexander study was designed to test if dual-targeting of CD19 and CD22 would reduce the likelihood of antigen escape.
Anti-BCMA CAR-T Deemed Effective in Heavily Pretreated, Refractory Multiple Myeloma
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Allogeneic CAR-T Therapies Appear Safe in LBCL/FL
The “universal” products have the potential to address the challenges of autologous CAR-T.
Anti-CD117 CAR T Cells Promising Immunotherapeutic Modality for AML
Generating CAR T cells against human cognate receptor CD117 may be a successful treatment for patients with AML.
Phase 2 Study of CPX-351 Results Promising in Relapsed Pediatric AML
Encouraging response rates in children with first relapse AML treated with CPX-351 followed by FLAG provide rationale for de novo AML study.
Preliminary Evidence Supports Benefit of Urinary-Derived hCG in Acute GVHD
In this phase I clinical trial, 2 different cohorts of patients with acute GVHD received subcutaneous injections of uhCG along with standard-of-care treatment.
Real-World Data Suggest Prolonged Lenalidomide Maintenance Therapy Is Beneficial in Patients With MRD-Positive Multiple Myeloma
Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Next post in Myeloma
